Compare · DFTX vs OBIO
DFTX vs OBIO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 13.6x OBIO ($339.0M).
- Over the past year, DFTX is up 187.5% and OBIO is up 55.8% - DFTX leads by 131.7 points.
- DFTX has been more active in the news (11 items in the past 4 weeks vs 4 for OBIO).
- OBIO has more recent analyst coverage (10 ratings vs 8 for DFTX).
PerformanceDFTX+187.49%OBIO+55.83%
2025-10-16+0.00%2026-10-15
- Company
- Definium Therapeutics Inc.
- Orchestra BioMed Holdings Inc.
- Price
- $34.26+0.04%
- $5.75+1.95%
- Market cap
- $4.60B
- $339.0M
- 1M return
- -9.38%
- -4.49%
- 1Y return
- +187.49%
- +55.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 4
- Recent ratings
- 8
- 10
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest OBIO
- Officer Sherman Darren sold $95,400 worth of shares (15,000 units at $6.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,119,402 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
- Officer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,067,463 units (SEC Form 4) (tax withholding)
- Orchestra BioMed upgraded by BTIG Research with a new price target
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Hochman David P bought $47,900 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.94% to 1,070,746 units (SEC Form 4)
- Officer Sherman Darren sold $74,100 worth of shares (15,000 units at $4.94) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,134,402 units (SEC Form 4)